Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MDM4 | O15151 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989142 | 0.87 | RAB9A (0.56) | RAB9ASMN1; SMN2NAPRTKMT2ANPC1 | |
| SCHEMBL13184552 | 0.82 | BAZ2B (0.57) | RAB9ASMN1; SMN2KMT2ANPC1MEN1 | |
| SCHEMBL1725139 | 0.82 | NAPRT (0.62) | RAB9ASMN1; SMN2NAPRTKMT2ANPC1 | |
| SCHEMBL31295356 | 0.81 | NAPRT (0.60) | RAB9ASMN1; SMN2NAPRTKMT2ANPC1 | |
| SCHEMBL13360508 | 0.81 | NAPRT (0.60) | RAB9ASMN1; SMN2NAPRTKMT2ANPC1 | |
| SCHEMBL931481 | 0.81 | NAPRT (0.60) | RAB9ASMN1; SMN2NAPRTKMT2ANPC1 | |
| SCHEMBL2981251 | 0.81 | NAPRT (0.60) | RAB9ASMN1; SMN2NAPRTKMT2ANPC1 | |
| SCHEMBL931076 | 0.80 | TDP1 (0.61) | RAB9ASMN1; SMN2NAPRTKMT2ANPC1 | |
| SCHEMBL13527490 | 0.80 | RAB9A (0.56) | RAB9ASMN1; SMN2NAPRTKMT2ANPC1 | |
| SCHEMBL3531806 | 0.80 | GAA (0.61) | RAB9ASMN1; SMN2NAPRTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6844366-B2 | Sulfonamide hydroxamates | SYNTEX (U.S.A.) LLC (US) | 2005-01-18 | — | — | US | claimed |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4630402-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2025-10-15 | — | — | EP | disclosed |
| US-20250282729-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | EUSTRALIS PHARMACEUTICALS LIMITED (TRADING AS PRESSURA NEURO) (AU) | 2025-09-11 | — | — | US | disclosed |
| US-12351557-B2 | Chemical compound manufacture, new salt form, and therapeutic uses thereof | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2025-07-08 | — | — | US | disclosed |
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | GENENTECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4448514-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401516-A | TYK2 inhibitors, compositions and methods thereof | 凌科药业(杭州)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2024121013-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2024-06-13 | — | — | WO | disclosed |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | CILAG AG (CH) | 2024-05-30 | — | — | US | disclosed |
| US-6297375-B1 | 4-phenyl-pyridine derivatives | HOFFMANN-LA ROCHE INC. | 2001-10-02 | — | — | US | disclosed |
| CN-1297887-A | Process for producing pyridine derivate | HOFFMANN LA ROCHE (CH) | 2001-06-06 | — | — | CN | disclosed |
| EP-1103546-A1 | Process for preparation of pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-05-30 | — | — | EP | disclosed |
| CN-1270959-A | 4-phenyl pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2000-10-25 | — | — | CN | disclosed |
| EP-1035115-A1 | 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-13 | — | — | EP | disclosed |
| US-4410530-A | CARDIO-SELECTIVE B-RECEPTOR BLOCKING AGENTS AND STIMULANTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| US-4195090-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4139623-A | HYPOTENSIVE AGENTS | C-G CORP. (US) | 1979-02-13 | — | — | US | disclosed |
| US-4115575-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-4027027-A | BETA-RECEPTOR-BLOCKERS, HYPOTENSIVES AND VALODILATORS; FOR TREATING ARRYTHMIAS AND ANGINA PECTORIS | CIBA-GEIGY CORPORATION (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425478-A1 | CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS | CDK2, CCNI, CDK20 | RAB9A 2194/4885SMN1; SMN2 1757/4885NAPRT 1290/4885 |
| US-20260070902-A1 | SULFONYL DERIVATIVES AS CCR6 INHIBITORS | CCR6, CCR1, CCR4 | RAB9A 2194/4885SMN1; SMN2 1277/4885NAPRT 2185/4885 |
| US-20250282729-A1 | CHEMICAL COMPOUND MANUFACTURE, NEW SALT FORM, AND THERAPEUTIC USES THEREOF | SCN5A, MGMT, NISCH | RAB9A 1880/4885SMN1; SMN2 2692/4885NAPRT 2078/4885 |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | RAB9A 1869/4885SMN1; SMN2 3406/4885NAPRT 2582/4885 |
| US-12351557-B2 | Chemical compound manufacture, new salt form, and therapeutic uses thereof | SCN5A, MGMT, NISCH | RAB9A 1880/4885SMN1; SMN2 2692/4885NAPRT 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.